Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Cash Flow (2016 - 2025)

Enanta Pharmaceuticals' Net Cash Flow history spans 14 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 89.09% year-over-year to $5.1 million; the TTM value through Dec 2025 reached -$47.5 million, down 206.99%, while the annual FY2025 figure was -$5.5 million, 88.49% up from the prior year.
  • Net Cash Flow reached $5.1 million in Q4 2025 per ENTA's latest filing, up from -$12.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $52.6 million in Q3 2021 to a low of -$72.5 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$745300.0, with a median of -$156500.0 recorded in 2022.
  • Peak YoY movement for Net Cash Flow: skyrocketed 513.43% in 2021, then plummeted 2466.63% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $41.9 million in 2021, then plummeted by 104.23% to -$1.8 million in 2022, then tumbled by 2466.63% to -$45.5 million in 2023, then surged by 203.65% to $47.1 million in 2024, then plummeted by 89.09% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Net Cash Flow are $5.1 million (Q4 2025), -$12.5 million (Q3 2025), and -$15.4 million (Q2 2025).